representative estimates. A two-tailed test was used to evaluate any change in rates over the study period.
The estimated number of dispensed buprenorphine/naloxone prescriptions nearly tripled from 2008 (3, 178, 571) to 2015 (9, 122, 150) . During 2008-2010, nearly all (97.6%) buprenorphine/naloxone prescriptions were dispensed as tablets in multidose bottles; by 2013-2015, most (86.9%) prescriptions were dispensed as unit-dose packaged tablets or film strips (Figure) . The approximate two thirds reduction in the rate of ED visits by children for buprenorphine/naloxone ingestions as the proportion of prescriptions dispensed in unit-dose packaging increased to over 80%, suggests that packaging/formulation changes might reduce pediatric ingestions. A study of poison center calls for pediatric buprenorphine/naloxone exposures also found a significantly lower rate of calls involving film strips in unit-dose packaging, compared with tablets in multidose bottles (6) . Other factors potentially contributing to the rate reduction include increased counseling of patients on safe use and storage (7) and a decline in pediatric medication ingestions overall (22% from 2010 to 2013) (8) .
FIGURE. Estimated rate of emergency department (ED) visits
Although substantially decreased, ED visits for pediatric ingestions of buprenorphine/naloxone were not eliminated after widespread adoption of unit-dose, child-resistant packaging. One explanation might be that some patients using buprenorphine/naloxone for medication-assisted treatment divide doses rather than consuming the entire unit, leaving unused partial doses accessible to children. In addition, the proportion of buprenorphine/naloxone prescriptions dispensed in unit-dose packaging began to decline at the end of 2013, reflecting the introduction of generic buprenorphine/naloxone tablets packaged in multidose bottles. Citing concern for pediatric exposures, the Massachusetts Office of Medicaid made unit-dose packaged products available to those in households with children aged <6 years (9) . At least one manufacturer of the generic product has voluntarily transitioned to unit-dose packaging, but others continue to use multidose bottles (7).
To improve access to medication-assisted treatment, the U.S. Department of Health and Human Services nearly tripled the maximum patient limit for buprenorphine prescribers in July 2016 (1) . As prescribing increases, and if multidose bottles again become the predominant form of packaging, it will be important to monitor the rate of ED visits for pediatric buprenorphine ingestions and respond if the rate increases.
